【摘要】 目的通过回顾性研究评价间质素阳性复发、转移恶性肿瘤MSLN eCAR T细胞治疗中的安全性临床研究。方法收集自2016年1月-2016年5月德州市人民医院复发、转移恶性肿瘤患者MSLN eCAR T细胞治疗的临床病理资料,回顾分析德州市人民医院患者MSLN eCAR T细胞治疗的不良反应事件和严重程度,不良反应的预防和处理方案。结果本组患者中不良反应事件和严重程度分别是:11例患者出现细胞因子释放综合征,1级10例患者,2级1例患者;4例患者出现1级到2级神经毒性;3例患者出现免疫相关不良反应,程度均较轻;无脱靶不良反应。所有患者不良反应可完全恢复。结论 MSLN eCAR T细胞治疗在间质素阳性复发、转移恶性肿瘤的安全性提供理论依据。更多还原

【Abstract】 Objective To evaluate the safety of MSLN eCAR T cells therapy for recurrent and metastatic malignant tumors by retrospective study. Methods The clinical and pathological data of MSLN eCAR T cells therapy for recurrent and metastatic malignant tumors in Dezhou People’s Hospital from January 2016 to May 2016 were collected. The adverse events and severity of MSLN e CAR T cells therapy in patients with malignant tumors in Dezhou People’s Hospital were retrospectively analyzed, and the prevention and treatment of adverse reactions were discussed. Results The adverse events and severity were as follows: 11 patients had cytokine release syndrome,10 patients with grade 1 and 1 patient with grade 2, 4 patients had grade 1 to grade 2 neurotoxicity, 3 patients had immune-related adverse reactions, the degree was mild, and there were no miss-target adverse reactions. Adverse reactions of all patients could be completely recovered. Conclusion MSLN e CAR T cells therapy provides a theoretical basis for the safety of interstitial hormone positive recurrence and metastasis of malignant tumors.更多还原